Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation
- 4 January 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Annals of Hematology
- Vol. 98 (5), 1177-1184
- https://doi.org/10.1007/s00277-018-3574-4
Abstract
Immunoparesis is defined as a reduction in the levels of one, two, or three uninvolved immunoglobulins. However, there are very limited data on the incidence and prognostic significance of immunoparesis recovery 1 year after autologous stem cell transplantation (ASCT) in MM. We reviewed medical records of de novo MM patients who received ASCT at Beijing Chao Yang hospital. One hundred eight MM patients were included in the study. Conventional chemotherapy was administered as induction regimen in 16 patients (14.8%), whereas novel agents were used in 92 patients (85.2%). Most patients had immunoparesis at diagnosis (89.1%) and at the moment of ASCT as well (75%). After a median follow-up of 49 months, in the group with immunoglobulin recovery 1 year after ASCT, there was a trend towards longer progression-free survival (PFS) than in the group with immunoparesis (P = 0.054). And overall survival (OS) was significantly longer in patients with immunoparesis recovery (P = 0.004). In multivariate analysis, immunoparesis recovery 1 year after ASCT was independently associated with improved OS (P = 0.016). In conclusion, lack of immunoparesis recovery 1 year after ASCT in MM patients is associated with significantly shorter OS and this group of patients needs new treatment strategy to improve the prognosis.Keywords
Funding Information
- basic and clinic research cooperation fund of capital medical universty (grant 2015, 15JL37)
- Students' research innovation project of Capital Medical University. (grant 2015, XSKY2015150)
This publication has 14 references indexed in Scilit:
- Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell MyelomaTransplantation and Cellular Therapy, 2014
- Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myelomaLeukemia, 2014
- Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disordersHaematologica-The Hematology Journal, 2012
- Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patientsLeukemia, 2012
- Assessment of Monoclonal Gammopathies by Nephelometric Measurement of Individual Immunoglobulin κ/λ RatiosClinical Chemistry, 2009
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Review of 1027 Patients With Newly Diagnosed Multiple MyelomaMayo Clinic Proceedings, 2003
- Altered cytokine activities are related to the suppression of synthesis of normal immunoglobulin in multiple myelomaAmerican Journal of Hematology, 1989
- Suppression of polyclonal immunoglobulins in multiple myeloma: Relationship to the staging and other manifestations at diagnosisClinical Immunology and Immunopathology, 1980
- Clinical Features of Patients with a Serum M ComponentActa Medica Scandinavica, 1978